171 results
Page 6 of 9
8-K
qn2lsu4qq31s5
23 Jul 20
Aravive Announces Successful Completion of Phase 1b Trial Evaluating AVB-500
7:05am
424B3
etb2vx6j8hxka3f0 hg
14 Jul 20
Prospectus supplement
4:05pm
UPLOAD
rfpog73s 0ae1
1 Jul 20
Letter from SEC
12:00am
8-K
EX-10.3
7biibk
9 Apr 20
Aravive Announces Board Composition and Executive Management Transitions
4:43pm
8-K
h1udesr61ru4wx
27 Mar 20
AVB-500 Phase 1b dose escalation ongoing at 20 mg/kg dose in platinum resistant ovarian cancer with potential for topline data in summer 2020
8:05am
8-K
40q yyep8j1d
18 Feb 20
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
8:10am
8-K
6dnv585w0vhja3b
13 Jan 20
Other Events
8:06am
8-K
EX-10.3
dhr1bxx8d
9 Jan 20
Aravive Announces Management Changes
4:59pm
8-K
qsv9bmv nsgd
20 Dec 19
Regulation FD Disclosure
8:10am
8-K
8t0tj
2 Dec 19
Other Events
5:18pm
8-K
EX-99.1
u0274u
27 Nov 19
Aravive Announces Proposed Public Offering of Common Stock
4:15pm
8-K
EX-1.1
s2lswr
27 Nov 19
Aravive Announces Proposed Public Offering of Common Stock
4:15pm
8-K
EX-99.2
n4o9x9izx6xdazppe
27 Nov 19
Aravive Announces Proposed Public Offering of Common Stock
4:15pm
424B5
ra4izkj
27 Nov 19
Prospectus supplement for primary offering
4:07pm
424B5
oh4na54tc4nzofvyk
26 Nov 19
Prospectus supplement for primary offering
5:18pm